This section explores emerging pathways and mechanisms relevant to CLL pathogenesis and resistance, focusing on small molecule targets beyond the well-established classes of covalent/non-covalent BTK inhibitors and BCL-2 inhibitors. Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.